ChloroquineV1, PubMed, Curation, bibRecord, 000080

Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.

Identifieur interne : 000080 ( PubMed/Curation ); précédent : 000079; suivant : 000081

Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.

Auteurs : Xiufeng Liu [République populaire de Chine] ; Juanjuan Wu [République populaire de Chine] ; Menglin Fan [République populaire de Chine] ; Chen Shen [République populaire de Chine] ; Wenling Dai [République populaire de Chine] ; Yini Bao [République populaire de Chine] ; Ji-Hua Liu [République populaire de Chine] ; Bo-Yang Yu [République populaire de Chine]

Source :

Cell death & disease [ 2041-4889 ] ; 2018.

RBID : pubmed:30323180

Descripteurs français

English descriptors

KwdEn :
- A549 Cells, Adenocarcinoma, Bronchiolo-Alveolar (drug therapy), Adenocarcinoma, Bronchiolo-Alveolar (genetics), Adenocarcinoma, Bronchiolo-Alveolar (metabolism), Adenocarcinoma, Bronchiolo-Alveolar (pathology), Animals, Antineoplastic Agents, Phytogenic (chemical synthesis), Antineoplastic Agents, Phytogenic (pharmacology), Artemisinins (chemical synthesis), Artemisinins (pharmacology), Autophagy (drug effects), Autophagy (genetics), Cell Cycle (drug effects), Cell Cycle (genetics), Gene Expression Regulation, Neoplastic, HMGB1 Protein (antagonists & inhibitors), HMGB1 Protein (genetics), HMGB1 Protein (metabolism), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (genetics), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Male, Mice, Mice, Nude, Microtubule-Associated Proteins (genetics), Microtubule-Associated Proteins (metabolism), Mitogen-Activated Protein Kinase 1 (genetics), Mitogen-Activated Protein Kinase 1 (metabolism), Mitogen-Activated Protein Kinase 3 (genetics), Mitogen-Activated Protein Kinase 3 (metabolism), Mitogen-Activated Protein Kinase 8 (genetics), Mitogen-Activated Protein Kinase 8 (metabolism), RNA, Small Interfering (genetics), RNA, Small Interfering (metabolism), Signal Transduction, Tumor Burden (drug effects), Vacuoles (drug effects), Vacuoles (metabolism), Vacuoles (ultrastructure), Xenograft Model Antitumor Assays.
MESH :
- chemical , antagonists & inhibitors : HMGB1 Protein.
- chemical , chemical synthesis : Antineoplastic Agents, Phytogenic, Artemisinins.
- drug effects : Autophagy, Cell Cycle, Tumor Burden, Vacuoles.
- drug therapy : Adenocarcinoma, Bronchiolo-Alveolar, Lung Neoplasms.
- genetics : Adenocarcinoma, Bronchiolo-Alveolar, Autophagy, Cell Cycle, HMGB1 Protein, Lung Neoplasms, Microtubule-Associated Proteins, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mitogen-Activated Protein Kinase 8, RNA, Small Interfering.
- metabolism : Adenocarcinoma, Bronchiolo-Alveolar, HMGB1 Protein, Lung Neoplasms, Microtubule-Associated Proteins, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Mitogen-Activated Protein Kinase 8, RNA, Small Interfering, Vacuoles.
- pathology : Adenocarcinoma, Bronchiolo-Alveolar, Lung Neoplasms.
- chemical , pharmacology : Antineoplastic Agents, Phytogenic, Artemisinins.
- ultrastructure : Vacuoles.
- A549 Cells, Animals, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Mice, Nude, Signal Transduction, Xenograft Model Antitumor Assays.

Abstract

Dihydroartemisinin (DHA) and its analogs are reported to possess selective anticancer activity. Here, we reported a novel DHA derivative DHA-37 that exhibited more potent anticancer activity on the cells tested. Distinct from DHA-induced apoptosis, DHA-37 triggered excessive autophagic cell death, and became the main contributor to DHA-37-induced A549 cell death. Incubation of the cells with DHA-37 but not DHA produced increased dots distribution of GFP-LC3 and expression ratio of LC3-II/LC3-I, and enhanced the formation of autophagic vacuoles as revealed by TEM. Treatment with the autophagy inhibitor 3-MA, LY294002, or chloroquine could reverse DHA-37-induced cell death. In addition, DHA-37-induced cell death was associated significantly with the increased expression of HMGB1, and knockdown of HMGB1 could reverse DHA-37-induced cell death. More importantly, the elevated HMGB1 expression induced autophagy through the activation of the MAPK signal but not PI3K-AKT-mTOR pathway. In addition, DHA-37 also showed a wonderful performance in A549 xenograft mice model. These findings suggest that HMGB1 as a target candidate for apoptosis-resistant cancer treatment and artemisinin-based drugs could be used in inducing autophagic cell death.

DOI: 10.1038/s41419-018-1006-y
PubMed: 30323180

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000080

Links to Exploration step

pubmed:30323180

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.</title>
<author><name sortKey="Liu, Xiufeng" sort="Liu, Xiufeng" uniqKey="Liu X" first="Xiufeng" last="Liu">Xiufeng Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wu, Juanjuan" sort="Wu, Juanjuan" uniqKey="Wu J" first="Juanjuan" last="Wu">Juanjuan Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fan, Menglin" sort="Fan, Menglin" uniqKey="Fan M" first="Menglin" last="Fan">Menglin Fan</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shen, Chen" sort="Shen, Chen" uniqKey="Shen C" first="Chen" last="Shen">Chen Shen</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dai, Wenling" sort="Dai, Wenling" uniqKey="Dai W" first="Wenling" last="Dai">Wenling Dai</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bao, Yini" sort="Bao, Yini" uniqKey="Bao Y" first="Yini" last="Bao">Yini Bao</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Ji Hua" sort="Liu, Ji Hua" uniqKey="Liu J" first="Ji-Hua" last="Liu">Ji-Hua Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China. liujihua@cpu.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yu, Bo Yang" sort="Yu, Bo Yang" uniqKey="Yu B" first="Bo-Yang" last="Yu">Bo-Yang Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30323180</idno>
<idno type="pmid">30323180</idno>
<idno type="doi">10.1038/s41419-018-1006-y</idno>
<idno type="wicri:Area/PubMed/Corpus">000080</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000080</idno>
<idno type="wicri:Area/PubMed/Curation">000080</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000080</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.</title>
<author><name sortKey="Liu, Xiufeng" sort="Liu, Xiufeng" uniqKey="Liu X" first="Xiufeng" last="Liu">Xiufeng Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wu, Juanjuan" sort="Wu, Juanjuan" uniqKey="Wu J" first="Juanjuan" last="Wu">Juanjuan Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fan, Menglin" sort="Fan, Menglin" uniqKey="Fan M" first="Menglin" last="Fan">Menglin Fan</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shen, Chen" sort="Shen, Chen" uniqKey="Shen C" first="Chen" last="Shen">Chen Shen</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dai, Wenling" sort="Dai, Wenling" uniqKey="Dai W" first="Wenling" last="Dai">Wenling Dai</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bao, Yini" sort="Bao, Yini" uniqKey="Bao Y" first="Yini" last="Bao">Yini Bao</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Liu, Ji Hua" sort="Liu, Ji Hua" uniqKey="Liu J" first="Ji-Hua" last="Liu">Ji-Hua Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China. liujihua@cpu.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yu, Bo Yang" sort="Yu, Bo Yang" uniqKey="Yu B" first="Bo-Yang" last="Yu">Bo-Yang Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Cell death & disease</title>
<idno type="eISSN">2041-4889</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A549 Cells</term>
<term>Adenocarcinoma, Bronchiolo-Alveolar (drug therapy)</term>
<term>Adenocarcinoma, Bronchiolo-Alveolar (genetics)</term>
<term>Adenocarcinoma, Bronchiolo-Alveolar (metabolism)</term>
<term>Adenocarcinoma, Bronchiolo-Alveolar (pathology)</term>
<term>Animals</term>
<term>Antineoplastic Agents, Phytogenic (chemical synthesis)</term>
<term>Antineoplastic Agents, Phytogenic (pharmacology)</term>
<term>Artemisinins (chemical synthesis)</term>
<term>Artemisinins (pharmacology)</term>
<term>Autophagy (drug effects)</term>
<term>Autophagy (genetics)</term>
<term>Cell Cycle (drug effects)</term>
<term>Cell Cycle (genetics)</term>
<term>Gene Expression Regulation, Neoplastic</term>
<term>HMGB1 Protein (antagonists & inhibitors)</term>
<term>HMGB1 Protein (genetics)</term>
<term>HMGB1 Protein (metabolism)</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (genetics)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Nude</term>
<term>Microtubule-Associated Proteins (genetics)</term>
<term>Microtubule-Associated Proteins (metabolism)</term>
<term>Mitogen-Activated Protein Kinase 1 (genetics)</term>
<term>Mitogen-Activated Protein Kinase 1 (metabolism)</term>
<term>Mitogen-Activated Protein Kinase 3 (genetics)</term>
<term>Mitogen-Activated Protein Kinase 3 (metabolism)</term>
<term>Mitogen-Activated Protein Kinase 8 (genetics)</term>
<term>Mitogen-Activated Protein Kinase 8 (metabolism)</term>
<term>RNA, Small Interfering (genetics)</term>
<term>RNA, Small Interfering (metabolism)</term>
<term>Signal Transduction</term>
<term>Tumor Burden (drug effects)</term>
<term>Vacuoles (drug effects)</term>
<term>Vacuoles (metabolism)</term>
<term>Vacuoles (ultrastructure)</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adénocarcinome bronchioloalvéolaire (anatomopathologie)</term>
<term>Adénocarcinome bronchioloalvéolaire (génétique)</term>
<term>Adénocarcinome bronchioloalvéolaire (métabolisme)</term>
<term>Adénocarcinome bronchioloalvéolaire (traitement médicamenteux)</term>
<term>Animaux</term>
<term>Antinéoplasiques d'origine végétale (pharmacologie)</term>
<term>Antinéoplasiques d'origine végétale (synthèse chimique)</term>
<term>Artémisinines (pharmacologie)</term>
<term>Artémisinines (synthèse chimique)</term>
<term>Autophagie ()</term>
<term>Autophagie (génétique)</term>
<term>Cellules A549</term>
<term>Charge tumorale ()</term>
<term>Cycle cellulaire ()</term>
<term>Cycle cellulaire (génétique)</term>
<term>Humains</term>
<term>Mitogen-Activated Protein Kinase 1 (génétique)</term>
<term>Mitogen-Activated Protein Kinase 1 (métabolisme)</term>
<term>Mitogen-Activated Protein Kinase 3 (génétique)</term>
<term>Mitogen-Activated Protein Kinase 3 (métabolisme)</term>
<term>Mitogen-Activated Protein Kinase 8 (génétique)</term>
<term>Mitogen-Activated Protein Kinase 8 (métabolisme)</term>
<term>Mâle</term>
<term>Petit ARN interférent (génétique)</term>
<term>Petit ARN interférent (métabolisme)</term>
<term>Protéine HMGB1 (antagonistes et inhibiteurs)</term>
<term>Protéine HMGB1 (génétique)</term>
<term>Protéine HMGB1 (métabolisme)</term>
<term>Protéines associées aux microtubules (génétique)</term>
<term>Protéines associées aux microtubules (métabolisme)</term>
<term>Régulation de l'expression des gènes tumoraux</term>
<term>Souris</term>
<term>Souris nude</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Transduction du signal</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (génétique)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
<term>Vacuoles ()</term>
<term>Vacuoles (métabolisme)</term>
<term>Vacuoles (ultrastructure)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>HMGB1 Protein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term>
<term>Artemisinins</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome bronchioloalvéolaire</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéine HMGB1</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term>
<term>Cell Cycle</term>
<term>Tumor Burden</term>
<term>Vacuoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma, Bronchiolo-Alveolar</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenocarcinoma, Bronchiolo-Alveolar</term>
<term>Autophagy</term>
<term>Cell Cycle</term>
<term>HMGB1 Protein</term>
<term>Lung Neoplasms</term>
<term>Microtubule-Associated Proteins</term>
<term>Mitogen-Activated Protein Kinase 1</term>
<term>Mitogen-Activated Protein Kinase 3</term>
<term>Mitogen-Activated Protein Kinase 8</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénocarcinome bronchioloalvéolaire</term>
<term>Autophagie</term>
<term>Cycle cellulaire</term>
<term>Mitogen-Activated Protein Kinase 1</term>
<term>Mitogen-Activated Protein Kinase 3</term>
<term>Mitogen-Activated Protein Kinase 8</term>
<term>Petit ARN interférent</term>
<term>Protéine HMGB1</term>
<term>Protéines associées aux microtubules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenocarcinoma, Bronchiolo-Alveolar</term>
<term>HMGB1 Protein</term>
<term>Lung Neoplasms</term>
<term>Microtubule-Associated Proteins</term>
<term>Mitogen-Activated Protein Kinase 1</term>
<term>Mitogen-Activated Protein Kinase 3</term>
<term>Mitogen-Activated Protein Kinase 8</term>
<term>RNA, Small Interfering</term>
<term>Vacuoles</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adénocarcinome bronchioloalvéolaire</term>
<term>Mitogen-Activated Protein Kinase 1</term>
<term>Mitogen-Activated Protein Kinase 3</term>
<term>Mitogen-Activated Protein Kinase 8</term>
<term>Petit ARN interférent</term>
<term>Protéine HMGB1</term>
<term>Protéines associées aux microtubules</term>
<term>Tumeurs du poumon</term>
<term>Vacuoles</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma, Bronchiolo-Alveolar</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term>
<term>Artémisinines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term>
<term>Artemisinins</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term>
<term>Artémisinines</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome bronchioloalvéolaire</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Vacuoles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>A549 Cells</term>
<term>Animals</term>
<term>Gene Expression Regulation, Neoplastic</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Nude</term>
<term>Signal Transduction</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Autophagie</term>
<term>Cellules A549</term>
<term>Charge tumorale</term>
<term>Cycle cellulaire</term>
<term>Humains</term>
<term>Mâle</term>
<term>Régulation de l'expression des gènes tumoraux</term>
<term>Souris</term>
<term>Souris nude</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Transduction du signal</term>
<term>Vacuoles</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dihydroartemisinin (DHA) and its analogs are reported to possess selective anticancer activity. Here, we reported a novel DHA derivative DHA-37 that exhibited more potent anticancer activity on the cells tested. Distinct from DHA-induced apoptosis, DHA-37 triggered excessive autophagic cell death, and became the main contributor to DHA-37-induced A549 cell death. Incubation of the cells with DHA-37 but not DHA produced increased dots distribution of GFP-LC3 and expression ratio of LC3-II/LC3-I, and enhanced the formation of autophagic vacuoles as revealed by TEM. Treatment with the autophagy inhibitor 3-MA, LY294002, or chloroquine could reverse DHA-37-induced cell death. In addition, DHA-37-induced cell death was associated significantly with the increased expression of HMGB1, and knockdown of HMGB1 could reverse DHA-37-induced cell death. More importantly, the elevated HMGB1 expression induced autophagy through the activation of the MAPK signal but not PI3K-AKT-mTOR pathway. In addition, DHA-37 also showed a wonderful performance in A549 xenograft mice model. These findings suggest that HMGB1 as a target candidate for apoptosis-resistant cancer treatment and artemisinin-based drugs could be used in inducing autophagic cell death.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30323180</PMID>
<DateCompleted><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>9</Volume>
<Issue>11</Issue>
<PubDate><Year>2018</Year>
<Month>10</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cell death & disease</Title>
<ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.</ArticleTitle>
<Pagination><MedlinePgn>1048</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-018-1006-y</ELocationID>
<Abstract><AbstractText>Dihydroartemisinin (DHA) and its analogs are reported to possess selective anticancer activity. Here, we reported a novel DHA derivative DHA-37 that exhibited more potent anticancer activity on the cells tested. Distinct from DHA-induced apoptosis, DHA-37 triggered excessive autophagic cell death, and became the main contributor to DHA-37-induced A549 cell death. Incubation of the cells with DHA-37 but not DHA produced increased dots distribution of GFP-LC3 and expression ratio of LC3-II/LC3-I, and enhanced the formation of autophagic vacuoles as revealed by TEM. Treatment with the autophagy inhibitor 3-MA, LY294002, or chloroquine could reverse DHA-37-induced cell death. In addition, DHA-37-induced cell death was associated significantly with the increased expression of HMGB1, and knockdown of HMGB1 could reverse DHA-37-induced cell death. More importantly, the elevated HMGB1 expression induced autophagy through the activation of the MAPK signal but not PI3K-AKT-mTOR pathway. In addition, DHA-37 also showed a wonderful performance in A549 xenograft mice model. These findings suggest that HMGB1 as a target candidate for apoptosis-resistant cancer treatment and artemisinin-based drugs could be used in inducing autophagic cell death.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Xiufeng</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Juanjuan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fan</LastName>
<ForeName>Menglin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Chen</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dai</LastName>
<ForeName>Wenling</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bao</LastName>
<ForeName>Yini</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Ji-Hua</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China. liujihua@cpu.edu.cn.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 210009, Nanjing, China. liujihua@cpu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Bo-Yang</ForeName>
<Initials>BY</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, 210009, Nanjing, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>10</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Cell Death Dis</MedlineTA>
<NlmUniqueID>101524092</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C477012">MAP1LC3A protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C502070">MAP1LC3B protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6A9O50735X</RegistryNumber>
<NameOfSubstance UI="C039060">dihydroartemisinin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="C000629649">MAPK3 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048055">Mitogen-Activated Protein Kinase 8</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002282" MajorTopicYN="N">Adenocarcinoma, Bronchiolo-Alveolar</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048055" MajorTopicYN="N">Mitogen-Activated Protein Kinase 8</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014617" MajorTopicYN="N">Vacuoles</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>01</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>08</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30323180</ArticleId>
<ArticleId IdType="doi">10.1038/s41419-018-1006-y</ArticleId>
<ArticleId IdType="pii">10.1038/s41419-018-1006-y</ArticleId>
<ArticleId IdType="pmc">PMC6189137</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Autophagy. 2010 Nov;6(8):1209-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20935509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Nov 9;7(1):15175</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29123239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25936818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2013 May;1(3):251-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24429131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cancer Biol. 2017 Oct;46:65-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28254675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2011 Aug;7(8):904-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21487246</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2014 Mar 4;19(3):539-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24606906</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2016 Dec;1863(12):3050-3064</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27666506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomed Biotechnol. 2012;2012:247597</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22174561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2014 Jun;13(6):1589-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24705351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest New Drugs. 2013 Feb;31(1):230-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22935909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Clin Exp Pathol. 2014 Dec 01;7(12):8684-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25674233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antioxid Redox Signal. 2011 Oct 15;15(8):2185-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21395369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nutr Biochem. 2017 Jan;39:145-155</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27840291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20699-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24302768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2010 Nov;6(8):1181-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20861675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E155-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26715748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancers (Basel). 2014 Sep 05;6(3):1769-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25198391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2017 May 2;8(18):30077-30091</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28404910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2015 Oct 6;6(30):28851-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26311737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2014 Feb 21;15(2):3145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24566140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2016;12(1):1-222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26799652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Oct 1;10(10):1873-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25126737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Environ Toxicol Pharmacol. 2016 Jul;45:202-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27318969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2015;11(7):1187-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26121576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2011 Oct 11;17(10):1217-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21989013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2013 Apr;9(4):451-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23388380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2015;11(7):1189-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26043873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2016 Jan 1;107:192-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26595184</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2013 Oct;13(10):714-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24060863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 1999 May;20(5):199-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10354615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2017 Jul;27(7):916-932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28374746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncotarget. 2016 Feb 16;7(7):8090-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26811496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2009 Jun 12;137(6):1001-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19524504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2008 Jan;52(1):98-109</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17938190</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Invest Ophthalmol Vis Sci. 2013 May 15;54(5):3400-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23611999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biol. 2010 Sep 6;190(5):881-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20819940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2016 Nov 10;123:763-768</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27537924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Physiol. 2015 Apr 07;6:93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25904867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Signal. 2014 Dec;26(12):2694-701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25173700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2017 May 18;18(5):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28524116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2014 Aug;14(8):535-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25056707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2014 Jul 01;4:5510</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24981420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2011 May 15;21(10):2882-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21489789</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000080 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000080 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:30323180
   |texte=   Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:30323180" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.

Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki